L.A.B. introduces in its multi-residue analysis the active ingredient Karanjin

L.A.B. | Laboratorio Analítico Bioclínico, fulfilling its commitment to its clients to improve its analytical services and in response to the recent requirement of the main supermarket chains and intermediaries, has introduced the active ingredient Karanjin in its multi-residue analysis. Karanjin is a type of flavonoid obtained from the seeds of the karanja tree (Millettia […]

continue reading

New progress on the stability indexes for EVOOs

Laboratorio Tello together with L.A.B. (both part of Tentamus Group) and the University of Granada, continue to advance in the development of stability indices on extra virgin olive oils and other vegetable oils.  Since 2018, Laboratorio Tello and L.A.B. are working on the public research project CASEITE of the call “RETOS Colaboración 2017″ next to the Analytical Chemistry Research Group FQM-232 (Analysis in Food and Environment of UGR) focussing on the […]

continue reading

FOOD & DRUG ANALYTICAL SERVICES LIMITED Announces Name Change to TENTAMUS PHARMA UK LIMITED

Food & Drug Analytical Services Limited (FDAS) has changed its name to Tentamus Pharma UK Limited.  This change marks five years following the successful acquisition by Tentamus Group GmbH. The new name better reflects the services and reflects the close relationship of the global Tentamus laboratory network. The Tentamus Group operates a worldwide network of […]

continue reading

Adamson Analytical Expands Wine, Pesticides, and Cosmetic Testing Capabilities

Adamson Analytical has been diligently at work to meet client needs in an unpredictable and ever-changing environment. This past year was especially challenging given the worldwide pandemic and wildfires throughout California. With many vineyards and vintners left scrambling to salvage their product and determine the extent of fire damage, Adamson stepped up to the plate. […]

continue reading

Risk evaluation of nitrosamines in pharmaceuticals

As of October 2020, EMA and the national competent authorities are asking marketing authorisation holders for metformin-containing medicines to test their medicines before releasing them onto the market. The risk evaluation for chemical medicines should be completed at the latest by 31 March 2021 and 1 July 2021 for biological medicines. If a risk is identified for an active substance, marketing authorisation holders […]

continue reading